Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15817655 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL15816725 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CB | |
| SCHEMBL15816727 | 0.92 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3CB | |
| SCHEMBL15815824 | 0.92 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL15815823 | 0.92 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL16293272 | 0.91 | PIK3CD (0.56) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL16293274 | 0.91 | PIK3CD (0.56) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL15816236 | 0.90 | PIK3CD (0.59) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL15816235 | 0.90 | PIK3CD (0.59) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB | |
| SCHEMBL15815857 | 0.89 | PIK3CD (0.46) | PIK3CDPIK3R1PIK3CGPIK3R2PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3R1 4/4885PIK3CG 10/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3R1 4/4885PIK3CG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.